At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 287 enrolled
Drug / intervention
10mg atorvastatin +7 moredrug
Likely dose
10mg atorvastatinfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
In Brief
A Phase 2 clinical trial evaluating 10mg atorvastatin, 80mg atorvastatin, and 6 other interventions for Dyslipidaemias and Dyslipidemias. Completed, enrolled 287 participants across 21 sites.
Detailed Summary
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidaemias, Dyslipidemias
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedOct 11, 2010
Enrollment StartSep 14, 2010
Primary CompletionJun 29, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.7 years ago
Interventions
10mg atorvastatindrug
10mg
80mg atorvastatindrug
80mg
GSK1292263 Placebodrug
Placebo
100mg GSK1292263drug
100mg
300mg GSK1292263drug
300mg
800mg GSK1292263drug
800mg
10mg ezetimibedrug
10mg
Washoutother
No interventions - washout period